Concepts (94)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Stroke | 8 | 2022 | 315 | 1.590 |
Why?
|
| Fibrinolytic Agents | 7 | 2022 | 63 | 1.080 |
Why?
|
| Tissue Plasminogen Activator | 6 | 2016 | 43 | 0.820 |
Why?
|
| Remote Consultation | 2 | 2016 | 12 | 0.660 |
Why?
|
| Subarachnoid Hemorrhage | 5 | 2019 | 68 | 0.620 |
Why?
|
| Thrombolytic Therapy | 5 | 2016 | 58 | 0.370 |
Why?
|
| Cerebral Hemorrhage | 3 | 2020 | 140 | 0.370 |
Why?
|
| Hospital Mortality | 3 | 2016 | 148 | 0.360 |
Why?
|
| Infarction, Middle Cerebral Artery | 4 | 2014 | 16 | 0.350 |
Why?
|
| Posterior Leukoencephalopathy Syndrome | 2 | 2019 | 11 | 0.280 |
Why?
|
| Vasospasm, Intracranial | 2 | 2019 | 18 | 0.270 |
Why?
|
| Middle Aged | 13 | 2022 | 10195 | 0.260 |
Why?
|
| Thrombectomy | 2 | 2017 | 31 | 0.260 |
Why?
|
| Aged | 12 | 2022 | 10048 | 0.250 |
Why?
|
| Time Factors | 6 | 2020 | 1672 | 0.220 |
Why?
|
| Retrospective Studies | 7 | 2022 | 3658 | 0.220 |
Why?
|
| beta-Alanine | 2 | 2012 | 3 | 0.210 |
Why?
|
| Benzimidazoles | 2 | 2012 | 11 | 0.200 |
Why?
|
| Severity of Illness Index | 3 | 2016 | 1133 | 0.200 |
Why?
|
| Pandemics | 2 | 2022 | 274 | 0.200 |
Why?
|
| Humans | 20 | 2022 | 30997 | 0.200 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2021 | 28 | 0.190 |
Why?
|
| Anticoagulants | 2 | 2012 | 108 | 0.190 |
Why?
|
| Female | 15 | 2021 | 16983 | 0.180 |
Why?
|
| Tertiary Care Centers | 1 | 2020 | 74 | 0.170 |
Why?
|
| Intracranial Thrombosis | 1 | 2019 | 6 | 0.170 |
Why?
|
| Endocarditis | 1 | 2019 | 10 | 0.170 |
Why?
|
| Male | 14 | 2020 | 16445 | 0.170 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2016 | 1311 | 0.170 |
Why?
|
| Brain Ischemia | 1 | 2020 | 75 | 0.170 |
Why?
|
| Atrial Fibrillation | 2 | 2012 | 207 | 0.160 |
Why?
|
| Acute Disease | 2 | 2016 | 231 | 0.150 |
Why?
|
| Cerebral Amyloid Angiopathy | 1 | 2019 | 120 | 0.150 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 101 | 0.150 |
Why?
|
| Nervous System Diseases | 1 | 2020 | 156 | 0.150 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 104 | 0.150 |
Why?
|
| International Normalized Ratio | 2 | 2014 | 24 | 0.140 |
Why?
|
| Arterial Occlusive Diseases | 1 | 2017 | 12 | 0.140 |
Why?
|
| Patient Transfer | 1 | 2017 | 21 | 0.140 |
Why?
|
| Informed Consent | 1 | 2015 | 22 | 0.130 |
Why?
|
| Socioeconomic Factors | 1 | 2016 | 335 | 0.120 |
Why?
|
| Cerebral Infarction | 1 | 2016 | 164 | 0.120 |
Why?
|
| Renal Dialysis | 1 | 2015 | 111 | 0.120 |
Why?
|
| Aged, 80 and over | 7 | 2019 | 5189 | 0.120 |
Why?
|
| Reperfusion | 1 | 2014 | 7 | 0.120 |
Why?
|
| Neoplasms | 1 | 2016 | 261 | 0.110 |
Why?
|
| Kidney Failure, Chronic | 1 | 2015 | 161 | 0.110 |
Why?
|
| Brain Edema | 1 | 2013 | 23 | 0.110 |
Why?
|
| Intracranial Hypertension | 1 | 2013 | 17 | 0.110 |
Why?
|
| Encephalocele | 1 | 2013 | 32 | 0.110 |
Why?
|
| Predictive Value of Tests | 3 | 2019 | 549 | 0.090 |
Why?
|
| Risk Factors | 4 | 2019 | 2588 | 0.090 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 2 | 2020 | 105 | 0.070 |
Why?
|
| Young Adult | 3 | 2019 | 2063 | 0.070 |
Why?
|
| Cerebral Angiography | 2 | 2019 | 33 | 0.070 |
Why?
|
| Adult | 5 | 2019 | 8931 | 0.070 |
Why?
|
| Treatment Outcome | 4 | 2017 | 3806 | 0.070 |
Why?
|
| Prospective Studies | 2 | 2020 | 1897 | 0.050 |
Why?
|
| Vasoconstriction | 1 | 2019 | 25 | 0.040 |
Why?
|
| Computed Tomography Angiography | 1 | 2019 | 35 | 0.040 |
Why?
|
| Syndrome | 1 | 2019 | 83 | 0.040 |
Why?
|
| Betacoronavirus | 1 | 2020 | 89 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2014 | 817 | 0.040 |
Why?
|
| Recurrence | 1 | 2019 | 370 | 0.040 |
Why?
|
| Comorbidity | 1 | 2020 | 508 | 0.040 |
Why?
|
| Sex Factors | 1 | 2019 | 511 | 0.040 |
Why?
|
| False Positive Reactions | 1 | 2017 | 36 | 0.040 |
Why?
|
| Chicago | 1 | 2020 | 943 | 0.040 |
Why?
|
| Reproducibility of Results | 1 | 2019 | 818 | 0.040 |
Why?
|
| Age Factors | 1 | 2019 | 873 | 0.030 |
Why?
|
| Statistics, Nonparametric | 1 | 2016 | 143 | 0.030 |
Why?
|
| Administration, Intravenous | 1 | 2015 | 28 | 0.030 |
Why?
|
| Ischemic Attack, Transient | 1 | 2015 | 21 | 0.030 |
Why?
|
| Adolescent | 1 | 2021 | 2401 | 0.030 |
Why?
|
| Fibrinogen | 1 | 2014 | 20 | 0.030 |
Why?
|
| Disability Evaluation | 1 | 2016 | 333 | 0.030 |
Why?
|
| Blood Coagulation Factors | 1 | 2014 | 19 | 0.030 |
Why?
|
| Early Diagnosis | 1 | 2014 | 69 | 0.030 |
Why?
|
| Triage | 1 | 2014 | 23 | 0.030 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2014 | 35 | 0.030 |
Why?
|
| Fatal Outcome | 1 | 2014 | 64 | 0.030 |
Why?
|
| Urban Population | 1 | 2014 | 148 | 0.030 |
Why?
|
| Ultrasonography, Doppler, Transcranial | 1 | 2012 | 9 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2012 | 70 | 0.030 |
Why?
|
| Partial Thromboplastin Time | 1 | 2012 | 4 | 0.030 |
Why?
|
| Platelet Count | 1 | 2012 | 22 | 0.030 |
Why?
|
| Dabigatran | 1 | 2012 | 7 | 0.030 |
Why?
|
| Cerebrovascular Circulation | 1 | 2012 | 43 | 0.030 |
Why?
|
| Data Interpretation, Statistical | 1 | 2012 | 100 | 0.030 |
Why?
|
| Blood Coagulation | 1 | 2012 | 20 | 0.030 |
Why?
|
| ROC Curve | 1 | 2012 | 145 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2014 | 718 | 0.020 |
Why?
|
| Brain | 1 | 2020 | 1801 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2012 | 2043 | 0.020 |
Why?
|